9,377 Shares of Royalty Pharma PLC $RPRX Acquired by Integrity Alliance LLC.

Integrity Alliance LLC. acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 9,377 shares of the biopharmaceutical company’s stock, valued at approximately $547,000.

A number of other institutional investors and hedge funds also recently modified their holdings of RPRX. Hsbc Holdings PLC lifted its holdings in shares of Royalty Pharma by 2,562.2% during the 1st quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock worth $74,000,000 after acquiring an additional 1,486,020 shares during the period. Renaissance Technologies LLC purchased a new stake in Royalty Pharma in the first quarter valued at approximately $37,941,000. Bank of America Corp DE grew its holdings in Royalty Pharma by 29.0% in the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after purchasing an additional 786,921 shares during the period. Carmignac Gestion acquired a new position in Royalty Pharma during the first quarter worth approximately $30,279,000. Finally, Congress Asset Management Co. acquired a new position in Royalty Pharma during the third quarter worth approximately $30,761,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $67.30 on Friday. The firm has a market capitalization of $38.70 billion, a P/E ratio of 56.08, a P/E/G ratio of 1.34 and a beta of 0.37. Royalty Pharma PLC has a 1-year low of $37.31 and a 1-year high of $69.77. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 2.80. The business’s 50-day simple moving average is $60.82 and its 200-day simple moving average is $53.81.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 30.04% and a net margin of 25.68%. Equities analysts predict that Royalty Pharma PLC will post 5.36 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is presently 78.33%.

Insider Buying and Selling

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares in the company, valued at $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 208,252 shares of company stock worth $12,324,407. 18.84% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

RPRX has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Morgan Stanley boosted their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. boosted their price objective on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. TD Cowen upped their price objective on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Finally, Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $63.29.

About Royalty Pharma

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding.

The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Founded in 1996 by Pablo Legorreta, the company became publicly listed in 2020.